Filing Flows › Arcadia Biosciences (RKDA) › Q4 2024
Arcadia Biosciences (RKDA) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 25, 2025
Arcadia Biosciences (RKDA) reported revenue of $1.2M for the fourth quarter 2024 (Q4 2024), +56% from a year earlier and -21% from the quarter before. Operating margin was -187.4%, net loss $4.1M (334.2% of revenue).
Arcadia Biosciences, Q4 2024: revenue $1.2M (+56% year over year), operating margin -187.4%, net loss $4.1M, operating cash flow −$2.2M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.2M | -21% | +56% |
| Operating profit | −$2.3M | — | — |
| Net earnings | −$4.1M | — | — |
| Operating cash flow | −$2.2M | — | — |
What changed
Revenue was $1.2M in Q4 2024, up 56% year over year and down 21% from the previous quarter.
Operating costs exceeded revenue by $2.3M, an operating margin of -187.4%. Total costs grew 77% against revenue growth of 56%. The fastest-growing cost line was Cost of revenue (+365%). The quarter ended with a net loss of $4.1M, wider than the previous quarter's $1.6M loss.
Operating cash flow was −$2.2M. Non-cash charges added back $117K of share-based compensation. Working capital and other items added $1.7M.
Questions
What was Arcadia Biosciences' revenue in the fourth quarter 2024?
Arcadia Biosciences (RKDA) reported revenue of $1.2M for the fourth quarter 2024 (Q4 2024), +56% from a year earlier and -21% from the quarter before.
Was Arcadia Biosciences profitable in the fourth quarter 2024?
Operating loss was $2.3M (-187.4% of revenue) and net loss $4.1M.